Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing motor fluctuations in adults with advanced Parkinson disease.
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
You May Also Like
Where can I buy Tobacco-Free Nicotine products?
February 27, 2025
Ozempic 用於什麼？
February 26, 2025
Global Launch Strategies in the Current Political Climate
February 19, 2025
+ There are no comments
Add yours